Taysha Gene Therapies Inc (TSHA)
3.62
+0.19
(+5.54%)
USD |
NASDAQ |
Jun 03, 16:00
3.65
+0.03
(+0.83%)
Pre-Market: 08:04
Taysha Gene Therapies Cash from Investing (TTM): -3.592M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -3.592M |
| December 31, 2023 | -7.352M |
| September 30, 2023 | -9.712M |
| June 30, 2023 | -9.242M |
| March 31, 2023 | -17.40M |
| December 31, 2022 | -24.93M |
| September 30, 2022 | -31.08M |
| Date | Value |
|---|---|
| June 30, 2022 | -32.06M |
| March 31, 2022 | -32.45M |
| December 31, 2021 | -21.55M |
| September 30, 2021 | -19.08M |
| June 30, 2021 | -15.11M |
| March 31, 2021 | -9.616M |
| December 31, 2020 | -9.082M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-32.45M
Minimum
Mar 2022
-3.592M
Maximum
Mar 2024
-17.31M
Average
-16.26M
Median
Cash from Investing (TTM) Benchmarks
| Aquestive Therapeutics Inc | -1.022M |
| Lifecore Biomedical Inc | -4.153M |
| Relmada Therapeutics Inc | 20.51M |
| ACADIA Pharmaceuticals Inc | -174.56M |
| Cyclacel Pharmaceuticals Inc | 0.00 |